NR

Neelam Rani

Active Director Director DIN 08119974
DIN 08119974 First appointment Apr 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Neelam Rani

Data last updated:

Neelam Rani is a Director at Biodecent Pharma Private Limited (since 2018). The company operates in Trading. Biodecent Pharma Private Limited reported revenue of ₹82.8 Lakh (FY 2025).

DIN 08119974
Primary Designation Director
Industry Trading
First Appointment 26 Apr 2018
Oldest Company Age 8 yrs
Largest company Biodecent Pharma Private Limited · ₹82.8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Biodecent Pharma Private Limited U51909HR2018PTC073803
Director26 Apr 20182018₹82.8 Lakh (FY 2025)Active

Board colleagues of Neelam Rani

NameDINCompanyDesignation
Sudhir Kumar08119973Biodecent Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Biodecent Pharma Private Limited
Premium access

Shareholding and investment profile for Neelam Rani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neelam Rani

Neelam Rani currently holds 1 directorship: Biodecent Pharma Private Limited (Director, since 26 Apr 2018, revenue ₹82.8 Lakh (FY 2025)).

Neelam Rani was first appointed on 26 Apr 2018 as Director at Biodecent Pharma Private Limited.

The current boards of Neelam Rani's companies include Sudhir Kumar (Biodecent Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available